erlotinib hydrochloride has been researched along with Carcinoma, Adenoid Cystic in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Gao, C; Ji, YX; Lan, KT; Nie, KK; Xu, J; Zhang, ZF | 1 |
Bell, D; Garber, ST; Janku, F; Khoury, L; McCutcheon, IE; Schomer, DF | 1 |
Dahse, R; Kosmehl, H | 1 |
3 other study(ies) available for erlotinib hydrochloride and Carcinoma, Adenoid Cystic
Article | Year |
---|---|
Successful Treatment of Erlotinib on Metastatic Adenoid Cystic Carcinoma of the Lacrimal Gland.
Topics: Antineoplastic Agents; Carcinoma, Adenoid Cystic; Erlotinib Hydrochloride; Eye Neoplasms; Humans; Lacrimal Apparatus | 2018 |
Metastatic Adenoid Cystic Carcinoma Mimicking Butterfly Glioblastoma: A Rare Presentation in the Splenium of the Corpus Callosum.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Adenoid Cystic; Chemotherapy, Adjuvant; Corpus Callosum; Cranial Irradiation; Decompression, Surgical; Diagnosis, Differential; Erlotinib Hydrochloride; Glioblastoma; Humans; Kidney Neoplasms; Lung Neoplasms; Maintenance Chemotherapy; Male; Metastasectomy; Parotid Neoplasms; Radiotherapy, Adjuvant | 2016 |
Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma.
Topics: Aged; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; DNA, Neoplasm; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Parotid Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |